vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.8倍（$324.4M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 5.7%，领先7.6%），Revolve Group, Inc.同比增速更快（10.4% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-13.3M），过去两年Revolve Group, Inc.的营收复合增速更高（9.5% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
AMPH vs RVLV — 直观对比
营收规模更大
RVLV
是对方的1.8倍
$183.1M
营收增速更快
RVLV
高出12.3%
-1.8%
净利率更高
AMPH
高出7.6%
5.7%
自由现金流更多
AMPH
多$37.9M
$-13.3M
两年增速更快
RVLV
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $324.4M |
| 净利润 | $24.4M | $18.6M |
| 毛利率 | 46.8% | 53.3% |
| 营业利润率 | 19.4% | 6.3% |
| 净利率 | 13.3% | 5.7% |
| 营收同比 | -1.8% | 10.4% |
| 净利润同比 | -35.7% | 50.4% |
| 每股收益（稀释后） | $0.51 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRVLV
| Q4 25 | $183.1M | $324.4M | ||
| Q3 25 | $191.8M | $295.6M | ||
| Q2 25 | $174.4M | $309.0M | ||
| Q1 25 | $170.5M | $296.7M | ||
| Q4 24 | $186.5M | $293.7M | ||
| Q3 24 | $191.2M | $283.1M | ||
| Q2 24 | $182.4M | $282.5M | ||
| Q1 24 | $171.8M | $270.6M |
净利润AMPHRVLV
| Q4 25 | $24.4M | $18.6M | ||
| Q3 25 | $17.4M | $21.2M | ||
| Q2 25 | $31.0M | $10.2M | ||
| Q1 25 | $25.3M | $11.8M | ||
| Q4 24 | $38.0M | $12.3M | ||
| Q3 24 | $40.4M | $11.0M | ||
| Q2 24 | $37.9M | $15.4M | ||
| Q1 24 | $43.2M | $10.9M |
毛利率AMPHRVLV
| Q4 25 | 46.8% | 53.3% | ||
| Q3 25 | 51.4% | 54.6% | ||
| Q2 25 | 49.6% | 54.1% | ||
| Q1 25 | 50.0% | 52.0% | ||
| Q4 24 | 46.5% | 52.5% | ||
| Q3 24 | 53.3% | 51.2% | ||
| Q2 24 | 52.2% | 54.0% | ||
| Q1 24 | 52.4% | 52.3% |
营业利润率AMPHRVLV
| Q4 25 | 19.4% | 6.3% | ||
| Q3 25 | 13.2% | 7.1% | ||
| Q2 25 | 24.2% | 5.8% | ||
| Q1 25 | 21.9% | 5.0% | ||
| Q4 24 | 24.2% | 3.9% | ||
| Q3 24 | 29.8% | 5.0% | ||
| Q2 24 | 30.3% | 5.8% | ||
| Q1 24 | 27.9% | 3.4% |
净利率AMPHRVLV
| Q4 25 | 13.3% | 5.7% | ||
| Q3 25 | 9.0% | 7.2% | ||
| Q2 25 | 17.8% | 3.3% | ||
| Q1 25 | 14.8% | 4.0% | ||
| Q4 24 | 20.4% | 4.2% | ||
| Q3 24 | 21.1% | 3.9% | ||
| Q2 24 | 20.8% | 5.4% | ||
| Q1 24 | 25.1% | 4.0% |
每股收益（稀释后）AMPHRVLV
| Q4 25 | $0.51 | $0.27 | ||
| Q3 25 | $0.37 | $0.29 | ||
| Q2 25 | $0.64 | $0.14 | ||
| Q1 25 | $0.51 | $0.16 | ||
| Q4 24 | $0.74 | $0.18 | ||
| Q3 24 | $0.78 | $0.15 | ||
| Q2 24 | $0.73 | $0.21 | ||
| Q1 24 | $0.81 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $292.3M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $512.5M |
| 总资产 | $1.6B | $765.0M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRVLV
| Q4 25 | $282.8M | $292.3M | ||
| Q3 25 | $276.2M | $315.4M | ||
| Q2 25 | $231.8M | $310.7M | ||
| Q1 25 | $236.9M | $300.8M | ||
| Q4 24 | $221.6M | $256.6M | ||
| Q3 24 | $250.5M | $252.8M | ||
| Q2 24 | $217.8M | $244.7M | ||
| Q1 24 | $289.6M | $273.4M |
总债务AMPHRVLV
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHRVLV
| Q4 25 | $788.8M | $512.5M | ||
| Q3 25 | $776.7M | $490.2M | ||
| Q2 25 | $757.5M | $468.6M | ||
| Q1 25 | $751.3M | $453.4M | ||
| Q4 24 | $732.3M | $437.8M | ||
| Q3 24 | $727.7M | $420.8M | ||
| Q2 24 | $713.3M | $405.8M | ||
| Q1 24 | $672.4M | $389.9M |
总资产AMPHRVLV
| Q4 25 | $1.6B | $765.0M | ||
| Q3 25 | $1.7B | $751.3M | ||
| Q2 25 | $1.6B | $722.9M | ||
| Q1 25 | $1.6B | $713.9M | ||
| Q4 24 | $1.6B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.5B | $657.8M | ||
| Q1 24 | $1.6B | $650.0M |
负债/权益比AMPHRVLV
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-13.3M |
| 自由现金流率自由现金流/营收 | 13.4% | -4.1% |
| 资本支出强度资本支出/营收 | 4.5% | 1.0% |
| 现金转化率经营现金流/净利润 | 1.35× | -0.55× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $48.0M |
8季度趋势，按日历期对齐
经营现金流AMPHRVLV
| Q4 25 | $32.9M | $-10.2M | ||
| Q3 25 | $52.6M | $11.8M | ||
| Q2 25 | $35.6M | $12.6M | ||
| Q1 25 | $35.1M | $45.1M | ||
| Q4 24 | $29.0M | $3.9M | ||
| Q3 24 | $60.0M | $9.1M | ||
| Q2 24 | $69.1M | $-24.7M | ||
| Q1 24 | $55.3M | $38.4M |
自由现金流AMPHRVLV
| Q4 25 | $24.6M | $-13.3M | ||
| Q3 25 | $47.2M | $7.5M | ||
| Q2 25 | $25.0M | $10.4M | ||
| Q1 25 | $24.4M | $43.4M | ||
| Q4 24 | $16.6M | $2.1M | ||
| Q3 24 | $46.2M | $8.0M | ||
| Q2 24 | $63.1M | $-25.7M | ||
| Q1 24 | $46.5M | $36.7M |
自由现金流率AMPHRVLV
| Q4 25 | 13.4% | -4.1% | ||
| Q3 25 | 24.6% | 2.5% | ||
| Q2 25 | 14.3% | 3.4% | ||
| Q1 25 | 14.3% | 14.6% | ||
| Q4 24 | 8.9% | 0.7% | ||
| Q3 24 | 24.1% | 2.8% | ||
| Q2 24 | 34.6% | -9.1% | ||
| Q1 24 | 27.1% | 13.5% |
资本支出强度AMPHRVLV
| Q4 25 | 4.5% | 1.0% | ||
| Q3 25 | 2.8% | 1.5% | ||
| Q2 25 | 6.1% | 0.7% | ||
| Q1 25 | 6.3% | 0.6% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 5.1% | 0.6% |
现金转化率AMPHRVLV
| Q4 25 | 1.35× | -0.55× | ||
| Q3 25 | 3.03× | 0.56× | ||
| Q2 25 | 1.15× | 1.24× | ||
| Q1 25 | 1.39× | 3.82× | ||
| Q4 24 | 0.76× | 0.32× | ||
| Q3 24 | 1.48× | 0.83× | ||
| Q2 24 | 1.82× | -1.60× | ||
| Q1 24 | 1.28× | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
